St. Jude/Cambridge Heart sales
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical will market Cambridge Heart's HearTwave II microvolt t-wave alternans test to North American primary care and internal medicine physicians under an amendment to the firms' three-year marketing agreement, they announce June 18. Under the original deal, signed in March, St. Jude was only to target electrophysiologists and cardiologists for sales of the product, which is used to stratify patients by risk for implantable defibrillator need (1"The Gray Sheet" March 26, 2007, p. 8). Cambridge Heart's reps, who originally addressed the primary care and internal medicine market, will now support St. Jude's team in all physician markets...
You may also be interested in...
T-Wave Alternans ICD Screening May Gain Traction With St. Jude Pact
St. Jude Medical's endorsement of microvolt t-wave alternans testing under a co-marketing agreement with test maker Cambridge Heart will help accelerate adoption of the technology, which guides appropriate defibrillator patient selection, both companies say
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.